Avaliação leucométrica e citofluorométrica do sangue periférico de cães com linfoma, após uso de rhG-CSF, submetidos à alta dose de ciclofosfamida seguida ou não de transplante autólogo de medula óssea

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Prevenção da repetição de reação tipo 2 da hanseníase com uso da talidomida na dose de 100mg/dia

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Avaliação da dose de radiação absorvida em exames radiológicos durante o planejamento radioterápico

Pós-graduação em Pesquisa e Desenvolvimento (Biotecnologia Médica) - FMB

Tomografia computadorizada Cone Beam em Ortodontia - evolução ou revolução? visão geral, aplicações, vantagens/desvantagens e dose de radiação

Introduction: The request of three-dimensional images (3D) of the dentomaxillofacial complex has increased. Hence, new possibilities for assessment, treatment as well as follow-up after treatment have increased their importance with the use of cone beam computed tomography (CBCT). The images in two dimensions (2D) have inherent problems that can be solved with treedimensional images assessment. Objectives: To clarify the main doubts about the operational mechanism of complementary diagnostic method; to explain the advantages and disadvantages, to discuss the effective radiation dose and possible applications in orthodontia. Conclusion: The information generated by 2D images from the CBCT does not show differences that may endanger the orthodontic planning when compared with the images of 2D conventional radiographs. The effective radiation dose received by the patient should not be considered as a limiting factor of the tomography exam request.

Prevenção da repetição de episódos de reação tipo 2 da Hanseníase com o uso da talidomida na dose de 100mg/dia

Introdução: A hanseníase é doença crônica que pode ter seu curso interrompido por episódios reacionais tipo 1 e 2 ou ENH, sendo que estes podem ser repetitivos, com conseqüentes danos ao paciente.A talidomida é a medicação de eleição para o controle, desde 1965. Objetivo: Evitar repetição de episódios reacionais. Material e Método: Após o controle da reação com dose tradicional, utilizou-se 100mg/d, pelo período de seis meses, com acompanhamento por seis meses após a suspensão. Resultados: Foram avaliados 42 pacientes MB, 39 (92,85%) da forma V e 3(7,15%) da D, que apresentaram ENH, como primeiro episódio ou repetição, 33(78,6%) do sexo masculino e9(21,4%) do feminino. As idades variaram de 18 a 84 anos, predomínio acima de 49 anos.Não se observou repetição em 100% dos pacientes durante o uso dessa dose.Durante a observação clinica, 33(78,6%)continuaram sem apresentar reação e9(21,4%), todos da forma V,a apresentaram, de forma leve,sem sinais e sintomas, controlada com antinflamatórios não hormonais. Não houve efeitos adversos. Conclusões: sugere-se o uso da talidomida, 100mg/ dia, como manutenção, que foi efetiva, impedindo a repetição das reações tipo 2.

Eficácia e segurança do Sirolimus associado a tacrolimus em baixas doses em paciente idoso transplantado renal

Pós-graduação em Fisiopatologia em Clínica Médica - FMB

Monte Carlo modeling of the patient and treatment delivery complexities for high dose rate brachytherapy

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Avaliação da dose de radiação: angiotomografia coronariana - métodos retrospectivo e prospectivo

The aim of this study was to evaluate the effective dose received by patients undergoing CCTA in both acquisition methods in the period June 1st to October 30th, 2013. Data collection was performed at the Clínica Sabedotti in Ponta Grossa/PR, with General Electric Equipment VCT XT, 64 detections lines. The effective dose was measured from the thirty cases randomly selected of Picture Archival and Communication System – PACS, reported by Dose Lenght Product (DLP) equipment for each examination and the conversion factor (EDLP) set by the European Commission for cardiac region (EDLP = 0.014). The results showed significant differences in radiation dose delivered to the patient according to the employee acquisition method, Retrospective or Prospective of ECG.

Revisión sistemática utilidad de asa y calcio con o sin vitamina d en la prevención de cáncer colorrectal y la recurrencia de pólipos adenomatosos en paciente con riesgo de padecer esta patología

Introducción: El cáncer colorrectal es una patología con alto impacto en la salud pública, debido a su prevalencia, incidencia, severidad, costo e impacto en la salud mental y física del individuo y la familia. Ensayos clínicos realizados en pacientes con antecedente de infarto al miocardio que consumían ácido acetil salicílico (asa), calcio con y sin vitamina D, mostraron asociación entre el consumo de estos medicamentos y disminución en la incidencia en cáncer colorrectal y pólipos adenomatosos. Objetivo: Evaluar la literatura sobre el uso de asa, calcio con y sin vitamina D con relación a su impacto en la prevención del cáncer colorrectal y pólipos adenomatosos. Métodos: Se realizó revisión sistemática buscando ensayos clínicos realizados en pacientes con factores de riesgo para cáncer colorrectal y pólipos adenomatosos que usaron asa, calcio con y sin vitamina D fueron incluidos. Resultados: se escogieron 105 para la revisión sistemática. Conclusiones: Es necesario desarrollar más estudios que lleven a evaluar el efecto protector de la aspirina, calcio y vitamina D. En los artículos revisados la aspirina a dosis de 81 a 325 mg día se correlaciona con reducción de riesgo de aparición de CRC aunque la dosis ideal, el tiempo de inicio y la duración de la ingesta continua no son claros. Hacen falta estudios que comparen poblaciones con ingesta de asa a diferentes dosis.

Predictive Value Of Phase I Trials For Safety In Later Trials And Final Approved Dose: Analysis Of 61 Approved Cancer Drugs.

Phase I trials use a small number of patients to define a maximum tolerated dose (MTD) and the safety of new agents. We compared data from phase I and registration trials to determine whether early trials predicted later safety and final dose. We searched the U.S. Food and Drug Administration (FDA) website for drugs approved in nonpediatric cancers (January 1990-October 2012). The recommended phase II dose (R2PD) and toxicities from phase I were compared with doses and safety in later trials. In 62 of 85 (73%) matched trials, the dose from the later trial was within 20% of the RP2D. In a multivariable analysis, phase I trials of targeted agents were less predictive of the final approved dose (OR, 0.2 for adopting ± 20% of the RP2D for targeted vs. other classes; P = 0.025). Of the 530 clinically relevant toxicities in later trials, 70% (n = 374) were described in phase I. A significant relationship (P = 0.0032) between increasing the number of patients in phase I (up to 60) and the ability to describe future clinically relevant toxicities was observed. Among 28,505 patients in later trials, the death rate that was related to drug was 1.41%. In conclusion, dosing based on phase I trials was associated with a low toxicity-related death rate in later trials. The ability to predict relevant toxicities correlates with the number of patients on the initial phase I trial. The final dose approved was within 20% of the RP2D in 73% of assessed trials.

The Effect Of Soy Dietary Supplement And Low Dose Of Hormone Therapy On Main Cardiovascular Health Biomarkers: A Randomized Controlled Trial.

To assess the effects of a soy dietary supplement on the main biomarkers of cardiovascular health in postmenopausal women compared with the effects of low-dose hormone therapy (HT) and placebo. Double-blind, randomized and controlled intention-to-treat trial. Sixty healthy postmenopausal women, aged 40-60 years, 4.1 years mean time since menopause were recruited and randomly assigned to 3 groups: a soy dietary supplement group (isoflavone 90mg), a low-dose HT group (estradiol 1 mg plus noretisterone 0.5 mg) and a placebo group. Lipid profile, glucose level, body mass index, blood pressure and abdominal/hip ratio were evaluated in all the participants at baseline and after 16 weeks. Statistical analyses were performed using the χ2 test, Fisher's exact test, Kruskal-Wallis non-parametric test, analysis of variance (ANOVA), paired Student's t-test and Wilcoxon test. After a 16-week intervention period, total cholesterol decreased 11.3% and LDL-cholesterol decreased 18.6% in the HT group, but both did not change in the soy dietary supplement and placebo groups. Values for triglycerides, HDL-cholesterol, glucose level, body mass index, blood pressure and abdominal/hip ratio did not change over time in any of the three groups. The use of dietary soy supplement did not show any significant favorable effect on cardiovascular health biomarkers compared with HT. The trial is registered at the Brazilian Clinical Trials Registry (Registro Brasileiro de Ensaios Clínicos - ReBEC), number RBR-76mm75.

The Real-life Experience With Cardiovascular Complications In The First Dose Of Fingolimod For Multiple Sclerosis.

Fingolimod is a new and efficient treatment for multiple sclerosis (MS). The drug administration requires special attention to the first dose, since cardiovascular adverse events can be observed during the initial six hours of fingolimod ingestion. The present study consisted of a review of cardiovascular data on 180 patients with MS receiving the first dose of fingolimod. The rate of bradycardia in these patients was higher than that observed in clinical trials with very strict inclusion criteria for patients. There were less than 10% of cases requiring special attention, but no fatal cases. All but one patient continued the treatment after this initial dose. This is the first report on real-life administration of fingolimod to Brazilian patients with MS, and one of the few studies with these characteristics in the world.

A Feasibility Study Of Fricke Dosimetry As An Absorbed Dose To Water Standard For 192ir Hdr Sources.

High dose rate brachytherapy (HDR) using 192Ir sources is well accepted as an important treatment option and thus requires an accurate dosimetry standard. However, a dosimetry standard for the direct measurement of the absolute dose to water for this particular source type is currently not available. An improved standard for the absorbed dose to water based on Fricke dosimetry of HDR 192Ir brachytherapy sources is presented in this study. The main goal of this paper is to demonstrate the potential usefulness of the Fricke dosimetry technique for the standardization of the quantity absorbed dose to water for 192Ir sources. A molded, double-walled, spherical vessel for water containing the Fricke solution was constructed based on the Fricke system. The authors measured the absorbed dose to water and compared it with the doses calculated using the AAPM TG-43 report. The overall combined uncertainty associated with the measurements using Fricke dosimetry was 1.4% for k = 1, which is better than the uncertainties reported in previous studies. These results are promising; hence, the use of Fricke dosimetry to measure the absorbed dose to water as a standard for HDR 192Ir may be possible in the future.

Relação dose-dependente do uso crônico de fenitoína e atrofia cerebelar em pacientes com epilepsia

The chronic treatment with phenytoin or the acute intoxication by this drug may cause permanent cerebellar injury with atrophy of cerebellum vermis and hemispheres, which can be detected by neuroimaging studies. The aim of the present study was to investigate the correlation between the dosage and duration of treatment with phenytoin and the occurrence of cerebellar atrophy. Sixty-six patients were studied and had their tomographies analyzed for cerebellar atrophy. Of the 66 patients studied, 18 had moderate/severe atrophy, 15 had mild atrophy and 33 were considered to be normal. The patients with moderate/severe atrophy were those with higher exposure to phenytoin (longer duration of treatment and higher total dosage) showing statistically significant difference when compared to patients with mild atrophy or without atrophy (p=0.02). Further, the patients with moderate/severe atrophy had serum levels of phenytoin statistically higher than those of patients with mild atrophy or without atrophy (p = 0.008). There was no association between other antiepileptic drugs dosage or duration of treatment and degree of cerebellar atrophy. We also found that older patients had cerebellar atrophy more frequently, indicating that age or duration of the seizure disorder may also be important in the determination of cerebellar degeneration in these patients. We conclude that although there is a possibility that repeated seizures contribute to cerebellar damage, long term exposure to phenytoin, particularly in high doses and toxic serum levels, cause cerebellar atrophy.

Acute psychotic disorders induced by topiramate: report of two cases

We report on two epileptic patients who developed acute psychosis after the use of topiramate (TPM). One patient exhibited severe psychomotor agitation, heteroaggressiveness, auditory and visual hallucinations as well as severe paranoid and mystic delusions. The other patient had psychomotor agitation, depersonalization, derealization, severe anxiety and deluded that he was losing his memory. Both patients had to be taken to the casualty room. After interruption of TPM in one patient and reduction of dose in the other, a full remission of the psychotic symptoms was obtained without the need of antipsychotic drugs. Clinicians should be aware of the possibility of development of acute psychotic symptoms in patients undergoing TPM treatment.